Navigation Links
Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting
Date:4/10/2013

April 10, 2013, New York, NY A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week's American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.

"With new immunotherapy agents available to help patients with melanoma, researchers are developing prognostic biomarkers to determine who will benefit most to fully realize the potential of these treatments," explained Jedd D. Wolchok, PhD, MD, director of Ludwig's Collaborative Laboratory at Memorial Sloan-Kettering Cancer Center during his presentations at AACR. "By identifying targeted combinations of agents, the immune response can be improved in certain patients with melanoma, the most dangerous form of skin cancer."

Developments in immunotherapeutic treatment of ovarian cancer was highlighted in a "Meet the Expert" session with George Coukos, PhD, MD, director of the Ludwig Center for Cancer Research of the University of Lausanne. His presentation educated on current progress and future prospects in vaccine and adoptive T-cell therapy development, as well as immunomodulatory therapy tools available for immediate clinical testing. "Ovarian cancer remains a very important therapeutic challenge," commented Dr. Coukos. "With no drugs approved in two decades in the U.S. and no therapeutic targets emerging from deep sequencing analyses, immunotherapy could offer a promising new approach."

Dr. Geoffrey Greene's team at the Ludwig Center at the University of Chicago analyzed epigenetic regulators called microRNAs little pieces of ribonucleic acid that are present in all the cells in the body to better understand treatment challenges of metastasis and chemotherapy resistance in patients with triple negative breast cancer.

"Our research used a novel huma
'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Ludwig cancer researchers honored among first class of fellows in AACR Academy
2. Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR
3. Report presents designs for study of cancer risks near US nuclear facilities
4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
5. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
6. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
7. Crop Science Society of America presents 2012 class of fellows
8. IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management
9. Choline supplementation during pregnancy presents a new approach to schizophrenia prevention
10. July meeting presents animal and dairy science
11. International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2015)... 18, 2015  Navitas today announced that ... the Submission Content Management webinar scheduled on ... forum. Dedicated to the Implementation of Regulatory Submission ... for industry, vendors, health authorities, consultants and ... towards a standard method of implementing electronic ...
(Date:8/17/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Q4 2015. The new marketing campaign is being spearheaded ... Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ... in retail driven marketing and brand awareness and has ...
(Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... demonstrated that morphine withdrawal complicates hepatitis C by suppressing ... Wang et al., Morphine withdrawal enhances hepatitis C virus ... The American Journal of Pathology and is accompanied by ... is common among intravenous drug users, with 70 to ...
... can result in two immune system disorders that ... severe infections, according to new findings reported in ... may lead to new diagnostic tests for these ... common variable immunodeficiency (CVID). Currently, doctors diagnose the ...
... a "time machine," assert Duke neuroscientists Catalin Buhusi and ... is essential to understanding all its functions. The brain's ... communicating, to orchestrating movement, to getting food, they said. ... Nature Reviews Neuroscience, Buhusi and Meck discuss the current ...
Cached Biology News:Hepatitis C complicated by morphine withdrawal 2Biologists Crack Genetic Code for Specialized Spider Silk 2Biologists Crack Genetic Code for Specialized Spider Silk 3What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 2What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 3What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 4
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... 27, 2015 GlassesOff (OTCBB: GLSO), a ... in the human vision system, announced today a partnership with ... Chris Paul to develop a new mobile app ... improve their real-life on-court performance. Vision is the ... is shooting a ball or blocking a pass. The critical ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... QC, May 19 /PRNewswire-FirstCall/ - Neptune Technologies & ... its consolidated financial results for the fiscal year ... EBITDA(1) and first-time profitability for the three-month period ... amended their stock option plan. , Neptune reports ...
... Reprints NRx for the Force.com AppExchange saves time for ... process from within Salesforce CRMSANTA MONICA, Calif., May 19 ... announced the availability of Reprints NRx for ... the Force.com platform, Reprints NRx for the AppExchange is ...
... Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq and MTA: ... Auction" tender offer (the "Exchange Offer") to increase the total ... stock, no par value (the "Common Stock"), and cash for ... the following outstanding series of its convertible notes (the "Notes"):, ...
Cached Biology Technology:Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 2Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 3Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 4Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 5Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 2Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 3Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 2Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 3Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 4Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 5
... system uses the Adept CE 4100 high pressure ... UV/Visible detector for added flexibility and utra low ... alternative to a photodiode array detection and provides ... is required for method development and for monitoring ...
... is a new product number, created ... If showing no availability yet, please ... (E6152) or contact customer service for ... diam. 11.25 6.40 in. ...
... numbers of samples may be carried out using ... attention. System control and data processing is ... The elegant, powerful and very easy to ... 98 and 2000., The supplied detector is the ...
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
Biology Products: